Skip to Content

Bryan K Kee, M.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1999 University of Louisville School of Medicine, Louisville, KY, MD, Medicine
1995 University of Kentucky, Lexington, KY, BS, Cum Laude, Chemical Engineering

Selected Publications

Peer-Reviewed Original Research Articles

1. Arnold SM, Rinehart JJ, Tsakalozou E, Eckardt JR, Fields SZ, Shelton BJ, DeSimone PA, Kee BK, Moscow JA, Leggas M. A phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin in adult patients with refractory or metastatic solid malignancies. Clin Cancer Res 16(2):673-80, 1/15/2010. e-Pub 1/12/2010. PMCID: PMC2831464.


1. George B, You Y, Viswanathan, Wen S, Baladandayuthapani V, Overman MJ, Kee, BK, Kopetz S, Eng C, Garrett CR. Survival advantage associated with palliative oophorectomy in patietnts with metastatic colorectal cancer (CRC) to the ovaries (mCRC-0): a single institution retrospective analysis. J Clin Oncol 29(Suppl 4) (#539), 7/2011.
2. Arnold SM, Horn J, Eckardt JR, Rinehart JJ, DeSimone P, Fields SZ, Kee BK, Moscow JA, Houchins JC, Leggas M. Clinical and pharmacokinetic (PK) findings in a phase I study of 7-t-butyldimethylsily1-10-hydroxycamptothecin (AR-67) in patients with refractory solid tumors. J Clin Oncol 27:15S (#2534), 2009.
3. Leggas M, Horn J, Tsakalozou E, Moscow JA, Fields SZ, Houchins JC, Eckardt JR, DeSimone P, Kee BK, Rinehart JJ, Arnold SM. Pharmacokinetics (PK) of the highly lipophilic and blood stable camptothecin AR-67 (7-t-butyldimethylsily1-10-hydroxycamptothecin) in adult patients with solid malignancies. J Clin Oncol 27:15S (#2546), 2009.

Last updated: 7/6/2015